AUPH News and Press, Aurinia Pharmaceuticals Inc From 11/02/21

AAWW, ACLS, ACRE, AGIO, AMRN, AMRX, ATH, ATY, AUPH, AUTL, AVA, BCRX, BDC, BDSI, BGCP, BIP, OTCPK:BMWYY, BR, BRSP, BWA, CDW, CIM, CIO, CLH, CLVS, CPRI, CRL, CRTO, CSTE, CTRA, CVE, CVS, CWH, DFIN, DISCA, OTCQX:DLAKF, OTCPK:DNNGY, DNOW, EAT, EMR, ES, ETR, EVRG, EVRI, EXC, EXPI, EYPT, FDP, FUN, F...

- Longest available outcomes data with LUPKYNIS will be presented virtually during American College of Rheumatology (ACR) Convergence 2021; final results expected by the end of 2021 – - Updated interim analysis shows sustained safety and tolerability of LUPKYNIS compare...

Aurinia Pharmaceuticals (NASDAQ:AUPH) fell 1.3% after GlaxoSmithKline (NYSE:GSK) denied a Mail report from Sunday that the company was considering a bid for the company. A GSK spokeswoman told Reuters the report isn't true. Aurinia (AUPH) gained last week after speculation that seve...

Aurinia Pharmaceuticals (NASDAQ:AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers, according to Cantor Fitgzerald. Aurinia rose 1.5%. Other companies that could be interested include Amgen (NASDAQ:AMGN), AbbVie (NYSE:ABBV), J...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded today at a new 52-week high of $32.65. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 4.4 million shares. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides produc...

Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 4.4% after speculation that several other pharma companies may be looking at the company. GlaxoSmithKline (NYSE:GSK), Roche (OTCQX:RHHBY) and Otsuka Pharmaceuticals (OTCPK:OTSKF)  are speculated are speculated to reviewing a poten...

Oppenheimer has downgraded Aurinia Pharmaceuticals (NASDAQ:AUPH) from outperform to perform following a report that the company may be acquired by Bristol-Myers Squibb (NYSE:BMY). In addition, the firm says that the current share price reflects appropriate valuation. Oppenheimer has a $32 pri...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its third quarter 2021 financial results on Wednesday, November 3, 2021, before the markets open. Aurinia’s management team will also host a conference call at 8:30 a.m....

Top Biotech Stocks To Consider Buying [Or Selling] This Week Depending on your investment appetite, the stock market offers various types of opportunities. Biotech stocks have a reputation for being a high-risk, high-reward kind of investment. Over the past two years, countless ...

Data to highlight the safety, tolerability and efficacy of LUPKYNIS in patients with lupus nephritis Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune diseas...